LabCorp warning
This article was originally published in The Gray Sheet
Executive Summary
FDA sends a warning letter to clinical lab giant Laboratory Corporation of America Sept. 29 for not obtaining clearance or approval to market its OvaSure ovarian cancer screening test, launched in June as a diagnostic service. In August, the agency had sent an "untitled" letter to LabCorp, charging the firm with marketing the test without proper clinical validation (1"The Gray Sheet" Aug. 25, 2008, p. 9). Last month, FDA officials had a face-to-face meeting with company executives. FDA typically does not enforce device review requirements for tests that are developed by a lab and offered as a service by that lab, but the warning letter points out that OvaSure was "designed, developed and validated" by Yale scientists
You may also be interested in...
FDA Questions LabCorp On Its Ovarian Cancer Test Service
FDA is charging clinical lab giant Laboratory Corporation of America with marketing a test for ovarian cancer without proper clinical validation
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.